Alethea Capital Management LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Alethea Capital Management LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 14,830 shares of the biopharmaceutical company's stock, valued at approximately $393,000. Pfizer makes up approximately 0.3% of Alethea Capital Management LLC's holdings, making the stock its 13th biggest position.

A number of other large investors have also recently made changes to their positions in PFE. Alteri Wealth LLC acquired a new stake in Pfizer in the fourth quarter valued at $546,000. American Trust Investment Advisors LLC raised its position in shares of Pfizer by 16.0% during the 4th quarter. American Trust Investment Advisors LLC now owns 38,499 shares of the biopharmaceutical company's stock worth $1,021,000 after acquiring an additional 5,305 shares in the last quarter. Aptus Capital Advisors LLC lifted its stake in Pfizer by 124.0% during the fourth quarter. Aptus Capital Advisors LLC now owns 223,203 shares of the biopharmaceutical company's stock worth $5,922,000 after purchasing an additional 123,543 shares during the last quarter. Anson Funds Management LP lifted its stake in Pfizer by 20.0% during the fourth quarter. Anson Funds Management LP now owns 120,000 shares of the biopharmaceutical company's stock worth $3,184,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Aspire Growth Partners LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $592,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 1.1 %

Shares of Pfizer stock opened at $24.19 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a market cap of $137.19 billion, a P/E ratio of 17.16, a PEG ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a fifty day moving average of $24.34 and a two-hundred day moving average of $25.75.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.82 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.11%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.06% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on PFE shares. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.